Comments
Glenmark Pharmaceuticals Ltd.’s shares were up by 1.24 per cent after the company was granted final approval by the U.S. FDA for Apremilast Tablets, including 10 mg, 20 mg, and 30 mg versions.
These tablets serve as the generic alternative to Amgen Inc.’s Otezla Tablets. Notably, the Otezla Tablets attained approximately $3.7 billion in annual sales as per IQVIATM data for the 12-month period concluding in August 2023. With a current lineup of 188 products authorised for distribution in the U.S. market and 50 ANDA’s pending approval, Glenmark remains committed to seeking external partnerships to enhance its existing portfolio.
The shares were up by 1.24 per cent to ₹807.35 at 11.17 am on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.